Valeritas (NSDQ:VLRX) touted today the publication of a retrospective analysis showing that adults with Type 2 diabetes experienced improved glycemic control using the V-Go wearable insulin delivery device and a physician-driven titration algorithm.
The proof-of-concept study was designed to assess the safety and efficacy of a doctor-driven insulin titration algorithm in adults who were prescribed V-Go. Researchers evaluated the participants’ clinical outcomes after four months.
After four months of V-Go plus insulin dose adjustments with the algorithm, 67% of participants had an A1c level of less than 7.5% compared to 13% at baseline, according to Valeritas. The company also reported that the prevalence of hypoglycemia dropped to 7% after four months compared to 23% at baseline.
“Titration of insulin is an important step to improving glycemic control. We are heartened by the impressive results demonstrated by combining a straightforward insulin titration algorithm with the simplicity of V-Go in patients with Type 2 diabetes to maximize results,” CEO John Timberlake said in prepared remarks.
Earlier this month, Valeritas priced a $36 million offering and posted its financial results for the third quarter, topping expectations on Wall Street.
